Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. develops next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted delivery and selective bioactivation in the ileum and colon, with clinical development focused on ulcerative colitis and Crohn’s disease.
Company news commonly covers PALI-2108 clinical and translational data, pharmacokinetic and biomarker findings, disease-conference presentations, clinical advisory activity and healthcare investor events. Updates also describe the company’s precision pharmacology strategy and the role of gut-targeted PDE4 inhibition in inflammatory bowel disease programs.
Palisade Bio (Nasdaq:PALI) reported Q1 2026 results and clinical updates for PALI-2108, its once-daily oral PDE4 inhibitor prodrug for IBD.
Phase 1a/1b is complete with supportive safety, exposure and pharmacodynamic data. INDs for Phase 2 UC and CD are planned in 2026, with trials starting 3Q 2026 and 1Q 2027, and primary efficacy readouts expected 2H 2027 and early 2028.
R&D expenses rose to $6.4M from $1.0M, and G&A to $4.4M from $1.4M. Cash and equivalents were $132.6M, expected to fund operations through the planned Phase 2 readouts.
Palisade Bio (NASDAQ: PALI) reported additional Phase 1a/b analyses of PALI-2108 showing colon-targeted activation, ~6-fold tissue-to-plasma exposure, and steady-state active metabolite (PALI-0008) troughs above IC90 supporting once-daily dosing. Biomarkers and histology improved: fecal calprotectin ~70% lower; Nancy, Robarts, and Geboes scores declined.
Findings presented at Digestive Disease Week 2026 support localized pharmacology and continued clinical development in ulcerative colitis.
Palisade Bio (NASDAQ: PALI) announced that data from its lead program, PALI-2108, will be presented as a poster at Digestive Disease Week 2026 on May 5, 2026. The poster covers translational Phase 1 findings showing clinical, histologic and biomarker improvement in ulcerative colitis.
Poster session: Mechanisms of IBD Therapeutics; time: May 5, 12:30–1:30 PM CDT; location: Poster Hall, Level 3, Hall F2, McCormick Place. Management and Clinical Advisory Board members will attend and meet with qualified investors.
Palisade Bio (Nasdaq: PALI) will present virtually at the Needham & Co. 25th Annual Healthcare Conference April 14–17, 2026. The company presentation by CEO JD Finley and President & Chief Medical Officer Dr. Mitchell Jones is scheduled for April 16, 2026, 2:15–2:55 PM ET in Track 3.
A live webcast will be available on the Events page of the Investors section at palisadebio.com, with a replay archived for a limited time. Management will be available for one-on-one meetings with qualified, registered investors.
Palisade Bio (Nasdaq: PALI) reported positive topline Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease on March 30, 2026. The 14-day study (n=5) showed favorable safety, a mean 47.5% reduction in SES-CD, 40% endoscopic response and remission rates, and pharmacokinetics supporting once-daily dosing with tissue levels above IC90.
Mean fecal calprotectin fell ~59%, ileal cAMP rose 41%, and ileal tissue exposure exceeded plasma (~3x ileum, ~5x colon). Company plans a Phase 2 in moderate-to-severe Crohn’s disease and will present data at upcoming conferences.
Palisade Bio (Nasdaq: PALI) announced management participation in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 PM EST in Boston (in-person presentation and meetings) and the Leerink Partners 2026 Global Healthcare Conference on March 8-11, 2026 in Miami (one-on-one meetings).
Investors registered for each event who wish to meet with management should contact the respective conference one-on-one desk to request a meeting. A webcast registration link is available for the TD Cowen presentation.
Palisade Bio (Nasdaq: PALI) presented Phase 1b translational data for PALI-2108 at ECCO 2026 showing rapid, colon‑targeted activity. Key findings included measurable clinical response within seven days, localized suppression of inflammatory and fibrotic gene programs in colon tissue, reduced PDE4B expression with increased tissue cAMP, and an encouraging safety profile across 89 subjects. Analyses showed downregulation of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling and reduced inflammatory cell signatures, while peripheral immune profiles remained largely unchanged, supporting a colon‑focused pharmacologic effect.
Palisade Bio (Nasdaq: PALI) appointed Bram Verstockt, MD, PhD, to its Clinical Advisory Board to strengthen clinical and translational expertise for PALI-2108.
The company plans a Phase 2 ulcerative colitis IND submission in the first half of 2026 and aims to advance PALI-2108 in UC and fibrostenotic Crohn’s disease.
Palisade Bio (Nasdaq: PALI) announced a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM–1:55 PM ET. CEO JD Finley and President/CMO Dr. Mitchell Jones will present.
The event includes analyst-led discussions, one-on-one investor meetings for registered attendees, a live webcast on the company Events page at palisadebio.com, and a replay archived for a limited time.
Palisade Bio (Nasdaq: PALI) will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation runs 12:40 PM–1:10 PM ET in Track 3 and will be webcast live. Management will also hold one-on-one in-person meetings with qualified investors. A replay will be archived for a limited time on the company’s Investors Events page at palisadebio.com.